332 related articles for article (PubMed ID: 38183103)
21. Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.
Sweha SR; Chung C; Natarajan SK; Panwalkar P; Pun M; Ghali A; Bayliss J; Pratt D; Shankar A; Ravikumar V; Rao A; Cieslik M; Wilder-Romans K; Scott AJ; Wahl DR; Jessa S; Kleinman CL; Jabado N; Mackay A; Jones C; Martinez D; Santi M; Judkins AR; Yadav VN; Qin T; Phoenix TN; Koschmann CJ; Baker SJ; Chinnaiyan AM; Venneti S
Sci Transl Med; 2021 Oct; 13(615):eabf7860. PubMed ID: 34644147
[TBL] [Abstract][Full Text] [Related]
22. Emerging Epigenetic Therapies for Brain Tumors.
Kukreja L; Li CJ; Ezhilan S; Iyer VR; Kuo JS
Neuromolecular Med; 2022 Mar; 24(1):41-49. PubMed ID: 34677796
[TBL] [Abstract][Full Text] [Related]
23. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
Kasper LH; Baker SJ
Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
[TBL] [Abstract][Full Text] [Related]
24. Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.
Kanwore K; Kanwore K; Adzika GK; Abiola AA; Guo X; Kambey PA; Xia Y; Gao D
Front Immunol; 2022; 13():831636. PubMed ID: 35392088
[TBL] [Abstract][Full Text] [Related]
25. BET inhibitors: a novel epigenetic approach.
Doroshow DB; Eder JP; LoRusso PM
Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
[TBL] [Abstract][Full Text] [Related]
26. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
27. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.
Jones C; Baker SJ
Nat Rev Cancer; 2014 Oct; 14(10):. PubMed ID: 25230881
[TBL] [Abstract][Full Text] [Related]
28. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
29. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
Maleszewska M; Kaminska B
Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
[TBL] [Abstract][Full Text] [Related]
30. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.
Gelato KA; Adler D; Ocker M; Haendler B
Expert Opin Ther Targets; 2016 Jul; 20(7):783-99. PubMed ID: 26799480
[TBL] [Abstract][Full Text] [Related]
31. Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications.
J Dabrowski M; Wojtas B
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31311166
[TBL] [Abstract][Full Text] [Related]
32. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
Enomoto T; Aoki M; Hamasaki M; Abe H; Nonaka M; Inoue T; Nabeshima K
Neurol Med Chir (Tokyo); 2020 Mar; 60(3):136-146. PubMed ID: 31902873
[TBL] [Abstract][Full Text] [Related]
33. EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Zhang L; Liu Y; Wang M; Wu Z; Li N; Zhang J; Yang C
J Mol Cell Biol; 2017 Dec; 9(6):477-488. PubMed ID: 29272522
[TBL] [Abstract][Full Text] [Related]
34. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
[TBL] [Abstract][Full Text] [Related]
35. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
36. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
37. HAUSP Is a Key Epigenetic Regulator of the Chromatin Effector Proteins.
Abdullah O; Alhosin M
Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052383
[TBL] [Abstract][Full Text] [Related]
38. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
[TBL] [Abstract][Full Text] [Related]
39. R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.
Sears TK; Woolard KD
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2275-2285. PubMed ID: 35467128
[TBL] [Abstract][Full Text] [Related]
40. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.
Rugo HS; Jacobs I; Sharma S; Scappaticci F; Paul TA; Jensen-Pergakes K; Malouf GG
Adv Ther; 2020 Jul; 37(7):3059-3082. PubMed ID: 32445185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
